News

TruGenomix Wins Southeast Life Sciences SE Color Pitch

The first SE Color Pitch event, hosted by Southeast Life Sciences, was held on June 24, 2021, featuring top minority-led, early-stage life science companies from the southeast United States.

The winner of the SE Color Pitch event, TruGenomix, which will receive the $10,000 prize, sponsored by Moderna. Presenting for TruGenomix was Charles Cathlin. CEO & Founder.

TruGenomix is a precision behavioral health company focused on advancing the diagnosis and treatment of mental health conditions such as post-traumatic stress disorder (PTSD). Our behavioral health platform incorporates our core products, TruGen-1and TruBase. TruGen-1 is a 1000 gene neuropsychiatric panel, designed in collaboration with Illumina, that includes our patented markers for PTSD predisposition. TruBase is our custom-built machine learning and bioinformatics engine, which is designed to support behavioral health research, clinical decision-making, and biomarker discovery.

See the presentation HERE.

Recent News

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza

08/18/2026

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients

08/14/2026

Transforming the finance function in life sciences: Empower scalable growth

Life sciences companies operate in one of the most complex business environments. Long R&D timelines, limited early-stage revenue, and dependence on external funding create a financial landscape where every decision carries strategic weight. In this context, finance is not a back-office function. It is an operational engine that drives whether a company survives, scales, or